HQP1351AG301: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (POLARIS-1)

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) (POLARIS-1)
Principal Investigator
Emadi, Ashkan
Phase
III (Cancer Control)
Age Group
Adult
Applicable Disease Sites
Leukemia
Participating Institutions
Mary Babb Randolph Cancer Center
Contacts
Caitlin Slack, BS
Clinical Research Coordinator
Email:

View on ClinicalTrials.gov

Quick Search

Use the full search for additional searching options.